Rise and shine, everyone, another busy day is on the way. We can tell, partly, because our short person is hunched over the laptop for hours of remote learning and our official mascot is furiously hunting for a breakfast of squirrels and chipmunks. As for us, we are brewing cups of stimulation as we prepare to stare at our to-do list. Our choice today is French vanilla spiked with oatmeal milk. Feel free to join us. Meanwhile, here are a few items of interest. Hope your day goes well and you conquer the world. And as always, stay safe and wear a mask. …

Well over one-quarter of all state lawmakers nationwide have accepted money from the pharmaceutical industry since the beginning of 2019, according to a new STAT examination. In several states, taking drug industry cash was more the norm than the exception: In Illinois, more than 79% of the state’s 177 elected lawmakers have cashed such a check. In California, over 85% of lawmakers have taken pharma money. The data reveal the drug industry has poured over $5 million into state legislators’ campaigns in the past two years alone.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy